A Phase 3 interventional study of Tezepelumab and Placebo in Moderate to Severe Asthma, sponsored by AstraZeneca. Completed at 15 sites in United States. Open to participants aged 12 Years to 21 Years. Per ClinicalTrials.gov, last updated 2023-06-22.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing tezepelumab in Asthma — 7 open to participants now, 8 under way, 5 of them phase 3. tezepelumab · Asthma.
Among the 28 studies testing tezepelumab in Asthma, this one is the 18th largest by enrollment, is one of 2 that started in 2021, is one of 16 in phase 3, and was the 14th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →7 of the 28 studies testing tezepelumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
University of Alberta · Sites in Canada
Ages 18–55
AstraZeneca · Sites in China
Ages 12–80
AstraZeneca · Sites in United States, Argentina, Brazil and 19 more countries
Ages 5–11
Qianfoshan Hospital · Sites in China
Ages 18–75
Qilu Pharmaceutical Co., Ltd.
Ages 18–80
By country, each count listing its studies:
tezepelumab: first FDA approval 2021 (TEZSPIRE), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 12 Years to 21 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2021.
This study's enrollment of 70 is below the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 121 across the 28 interventional studies. Of the 19 that completed or were terminated, 15 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 28 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 166th largest by enrollment of the 248 interventional ones that give a count, is one of 14 that started in 2021, is one of 121 in phase 3, and was the 282nd registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
3 of the studies testing tezepelumab in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
| NCT06705764University of AlbertaTezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA) | 2026-11 |
| NCT07757841Qianfoshan HospitalReal-World Effectiveness of Tezepelumab in Allergic Bronchopulmonary Aspergillosis | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 28 studies testing tezepelumab in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3b, multicenter, randomized, double-blind, parallel group, placebo-controlled study designed to investigate the potential effect of tezepelumab (210 mg subcutaneous [SC] every 4 weeks [Q4W]) on antibody responses following seasonal quadrivalent influenza virus vaccination in the fall/winter 2021-2022 in the USA.
Participants with moderate to severe asthma will enter the screening period of a minimum of 2 weeks to allow adequate time for all of the eligibility criteria to be evaluated. They will be randomized 1:1 to receive tezepelumab 210 mg or placebo SC Q4W, administered at Weeks 0, 4, 8 and 12. Randomization will be monitored to ensure at least 50% of the randomized participants are between the ages of 12 to 17 years.
Participants will receive a single dose of inactivated quadrivalent seasonal influenza vaccine intramuscularly at Week 12, prior to the fourth dose of study intervention.
Serum samples for evaluation of antibody response will be drawn at Week 12 (pre-vaccination) and at Week 16 (4 weeks post-vaccination) when humoral response to the vaccination is expected to be fully developed.
The End of Treatment (EOT) Visit will be conducted at Week 16 and a final Follow-up Visit and the End of Study Visit will be conducted at Week 28.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be randomized to receive tezepelumab 210 mg administered at Weeks 0, 4, 8 and 12. Participants will also receive a single dose of inactivated quadrivalent seasonal influenza vaccine intramuscularly at Week 12, prior to the fourth dose of study intervention.
Drug: Tezepelumab
Participants will be randomized to receive placebo SC Q4W, administered at Weeks 0, 4, 8 and 12. Participants will also receive a single dose of inactivated quadrivalent seasonal influenza vaccine intramuscularly at Week 12, prior to the fourth dose of study intervention.
Drug: Placebo
210 mg SC injection Q4W.
SC injection Q4W.
Post-vaccination Strain-specific Hemagglutination Inhibition (HAI) Antibody Geometric Mean Fold Rises (GMFRs)
Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed. HAI assay was not performed for H3N2 strain due to the known low haemagglutination effect.
Time frame: From Week 12 to Week 16
Post-vaccination Strain-specific Microneutralization (MN) Antibody GMFRs
Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed.
Time frame: From Week 12 to Week 16
Post-vaccination Strain-specific Serum HAI Antibody Geometric Mean Titers (GMTs)
Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed. HAI assay was not performed for H3N2 strain due to the known low haemagglutination effect.
Time frame: Week 16
Post-vaccination Strain-specific Serum MN Antibody GMTs
Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed.
Time frame: Week 16
Percentage of Patients With Post-vaccination Strain-specific Antibody Response at Week 16 With Antibody Response Defined as a ≥ 4-fold Rise in HAI Antibody Titer
Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed. HAI assay was not performed for H3N2 strain due to the known low haemagglutination effect.
Time frame: Week 16
Percentage of Patients With Post-vaccination Strain-specific Antibody Response at Week 16 With Antibody Response Defined as a ≥ 4-fold Rise in MN Antibody Titer
Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed. Vaccine immunogenicity analysis set consisted of all randomised patients who received the influenza vaccine plus at least 1 dose of tezepelumab or placebo, had pre and post vaccination HAI or MN antibody measurements, had no influenza infection prior to Visit 7 (Week 16), and had no protocol deviation, judged to have the potential to interfere with the generation or interpretation of an antibody response.
Time frame: Week 16
Percentage of Patients With Post-vaccination Strain-specific HAI Antibody Titer ≥ 40
Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed. HAI assay was not performed for H3N2 strain due to the known low haemagglutination effect.
Time frame: Week 16
Percentage of Patients With Post-vaccination Strain-specific MN Antibody Titer ≥ 40
Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed.
Time frame: Week 16
Serum Tezepelumab Concentrations
Tezepelumab serum concentrations were summarized using descriptive statistics at each visit.
Time frame: Week 0, Week 12, Week 16 and Week 28
Immunogenicity
Immunogenicity assessments were performed. ADA prevalence was defined as patients who are ADA positive at any time including baseline. Persistently positive was defined as having at least two post-baseline ADA positive measurements (with ≥16 weeks between first and last positive) or an ADA positive result at the last available post-baseline assessment. Transiently positive was defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. Treatment boosted ADA was defined as baseline positive ADA titre that was boosted to a 4-fold or higher-level following treatment. Treatment emergent ADA (ADA incidence) was defined as the sum of treatment induced ADA and treatment boosted ADA.
Time frame: From Baseline to Week 28
This study was conducted in 15 study centres in the United States between 23 August 2021 and 18 July 2022.
| Milestone | Tezepelumab | Placebo |
|---|---|---|
| Started | 35 | 35 |
| Completed | 34 | 34 |
| Not completed | 1 | 1 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed. HAI assay was not performed for H3N2 strain due to the known low haemagglutination effect.
| Fold change | Tezepelumab | Placebo |
|---|---|---|
| Influenza A H1N1 | 7.34 ± 1.361 | 4.75 ± 1.455 |
| Influenza B Yamagata Lineage | 1.76 ± 0.955 | 1.46 ± 0.937 |
| Influenza B Victoria Lineage | 2.94 ± 1.054 | 2.90 ± 0.841 |
Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed.
| Fold change | Tezepelumab | Placebo |
|---|---|---|
| Influenza A H1N1 | 14.56 ± 2.581 | 10.62 ± 2.409 |
| Influenza A H3N2 | 4.73 ± 1.509 | 5.90 ± 3.180 |
| Influenza B Yamagata Lineage | 4.00 ± 1.541 | 3.56 ± 2.206 |
| Influenza B Victoria Lineage | 4.08 ± 2.279 | 5.04 ± 1.723 |
Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed. HAI assay was not performed for H3N2 strain due to the known low haemagglutination effect.
| Titer | Tezepelumab | Placebo |
|---|---|---|
| Influenza A H1N1 | 809.23 ± 0.921 | 596.76 ± 1.076 |
| Influenza B Yamagata Lineage | 167.46 ± 0.925 | 161.56 ± 0.688 |
| Influenza B Victoria Lineage | 194.68 ± 1.089 | 200.55 ± 0.948 |
Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed.
| Titer | Tezepelumab | Placebo |
|---|---|---|
| Influenza A H1N1 | 382.55 ± 1.469 | 303.63 ± 1.667 |
| Influenza A H3N2 | 600.92 ± 2.154 | 457.33 ± 2.336 |
| Influenza B Yamagata Lineage | 355.44 ± 1.076 | 366.81 ± 1.270 |
| Influenza B Victoria Lineage | 125.67 ± 4.687 | 124.35 ± 3.515 |
Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed. HAI assay was not performed for H3N2 strain due to the known low haemagglutination effect.
| Percentage of participants | Tezepelumab | Placebo |
|---|---|---|
| Influenza A H1N1 | 78.8 ± 63.82 | 51.5 ± 36.07 |
| Influenza B Yamagata Lineage | 15.2 ± 6.17 | 15.2 ± 6.17 |
| Influenza B Victoria Lineage | 30.3 ± 17.46 | 39.4 ± 25.11 |
Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed. Vaccine immunogenicity analysis set consisted of all randomised patients who received the influenza vaccine plus at least 1 dose of tezepelumab or placebo, had pre and post vaccination HAI or MN antibody measurements, had no influenza infection prior to Visit 7 (Week 16), and had no protocol deviation, judged to have the potential to interfere with the generation or interpretation of an antibody response.
| Percentage of participants | Tezepelumab | Placebo |
|---|---|---|
| Influenza A H1N1 | 81.8 ± 67.24 | 75.8 ± 60.49 |
| Influenza A H3N2 | 60.6 ± 44.82 | 51.5 ± 36.07 |
| Influenza B Yamagata Lineage | 51.5 ± 36.07 | 36.4 ± 22.50 |
| Influenza B Victoria Lineage | 54.5 ± 38.94 | 63.6 ± 47.84 |
Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed. HAI assay was not performed for H3N2 strain due to the known low haemagglutination effect.
| Percentage of participants | Tezepelumab | Placebo |
|---|---|---|
| Influenza A H1N1 | 100 ± 91.32 | 100 ± 91.32 |
| Influenza B Yamagata Lineage | 97 ± 86.41 | 100 ± 91.32 |
| Influenza B Victoria Lineage | 100 ± 91.32 | 97.0 ± 86.41 |
Effect of tezepelumab on the humoral immune response following seasonal influenza virus vaccination in adolescent and young adult participants with moderate to severe asthma was assessed.
| Percentage of participants | Tezepelumab | Placebo |
|---|---|---|
| Influenza A H1N1 | 100 ± 91.32 | 93.9 ± 82.13 |
| Influenza A H3N2 | 93.9 ± 82.13 | 97 ± 86.41 |
| Influenza B Yamagata Lineage | 97 ± 86.41 | 100 ± 91.32 |
| Influenza B Victoria Lineage | 78.8 ± 63.82 | 81.8 ± 67.24 |
Tezepelumab serum concentrations were summarized using descriptive statistics at each visit.
| microgram/milliliter (μg/mL) | Tezepelumab |
|---|---|
| Week 0 | NA ± NA |
| Week 12 | 27.00 ± 0.5421 |
| Week 16 | 20.76 ± 3.6969 |
| Week 28 | 2.79 ± 1.0705 |
Immunogenicity assessments were performed. ADA prevalence was defined as patients who are ADA positive at any time including baseline. Persistently positive was defined as having at least two post-baseline ADA positive measurements (with ≥16 weeks between first and last positive) or an ADA positive result at the last available post-baseline assessment. Transiently positive was defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. Treatment boosted ADA was defined as baseline positive ADA titre that was boosted to a 4-fold or higher-level following treatment. Treatment emergent ADA (ADA incidence) was defined as the sum of treatment induced ADA and treatment boosted ADA.
| Patients | Tezepelumab | Placebo |
|---|---|---|
| ADA prevalence | 0 | 4 |
| Only baseline ADA positive | 0 | 0 |
| Both baseline and post-baseline ADA positive | 0 | 0 |
| Any baseline ADA positive | 0 | 0 |
| Any post-baseline ADA positive | 0 | 4 |
| Treatment-induced ADA positive | 0 | 4 |
| ADA persistently positive | 0 | 4 |
| ADA transiently positive | 0 | 0 |
| Treatment-boosted ADA positive | 0 | 0 |
| TE-ADA positive (ADA incidence) | 0 | 4 |
Collected over From the date of the first dose of study drug, throughout the treatment period up to the follow-up period or end of the study visit (Week 28). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tezepelumab | 0/35 (0%) | 0/35 (0%) | 14/35 (40%) |
| Placebo | 1/35 (2.9%) | 1/35 (2.9%) | 15/35 (42.9%) |
| Event | Tezepelumab | Placebo |
|---|---|---|
| Stab woundInjury, poisoning and procedural complications | 0/35 | 1/35 |
| Event | Tezepelumab | Placebo |
|---|---|---|
| COVID-19Infections and infestations | 8/35 | 8/35 |
| Acute sinusitisInfections and infestations | 3/35 | 0/35 |
| Ear infectionInfections and infestations | 1/35 | 2/35 |
| Viral upper respiratory tract infectionInfections and infestations | 1/35 | 2/35 |
| PharyngitisInfections and infestations | 0/35 | 2/35 |
| SinusitisInfections and infestations | 0/35 | 2/35 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/35 | 2/35 |
| Skin lacerationInjury, poisoning and procedural complications | 2/35 | 0/35 |
All patients randomised and receiving any study intervention were included in the Full analysis set, irrespective of their CSP adherence and continued participation in the study.
| Age, Continuous(years) | Tezepelumab | Placebo | Total |
|---|---|---|---|
| Mean | 16.3 ± 2.3 | 16.6 ± 3.1 | 16.5 ± 3.0 |
| Age, Customized(Participants) | Tezepelumab | Placebo | Total |
|---|---|---|---|
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 22 | 21 | 43 |
| Adults (18-64 years) | 13 | 14 | 27 |
| From 65-84 years | 0 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Tezepelumab | Placebo | Total |
|---|---|---|---|
| Female | 14 | 11 | 25 |
| Male | 21 | 24 | 45 |
| Ethnicity (NIH/OMB)(Participants) | Tezepelumab | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 8 | 10 | 18 |
| Not Hispanic or Latino | 27 | 25 | 52 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Tezepelumab | Placebo | Total |
|---|---|---|---|
| White | 24 | 23 | 47 |
| Black or African American | 8 | 12 | 20 |
| Asian | 1 | 0 | 1 |
| American Indian or Alaska Native | 2 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com /ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com /ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at: https://astrazenecagrouptrials.pharmacm.com /ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Aug 2021 to primary completion in Mar 2022, 6 months.
Results were first posted in Apr 2023, 1 year 1 month after primary completion.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 6 months is below that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tezepelumab